Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients
European Surgical Research · 2023
DOI: 10.1159/000533594 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Surgical Research, 2023. Verfasst von Lingna Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, The Affiliated Hospital of Ningbo University, LiHuiLi Hospital, Ningbo, China. Hauptthemen laut MEDLINE: Crohn Disease, Sepsis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The impact of ustekinumab (UST) therapy on surgical complications in patients with Crohn’s disease (CD) remains controversial. The aim of this meta-analysis is to explore the link between these two.
Methods
Databases (PubMed, Web of Science, Cochrane, and Springer Link) were searched until April 2022. Studies of CD patients who received UST and no UST prior to surgery (including no biological therapy, anti-tumor necrosis factor-α [anti-TNF-α] agent, and vedolizumab [VDZ]) were included. Primary outcomes included overall complications, infectious complications, and noninfectious complications.
Results
Nine studies totaling 3,225 CD patients were enrolled; 332 patients received UST treatment. There was no evidence of difference in the overall complications (odds ratio [OR] = 0.84, p = 0.37, 95% confidence interval [CI] = [0.57–1.23], I2 = 40%) between CD patients who had UST treatment preoperatively and those who had no UST treatment. There was no evidence of a difference in infectious complications (OR = 1.15, p = 0.35, 95% CI = [0.86–1.53], I2 = 2%). Additionally, there was no significant evidence of difference between these groups in terms of noninfectious complications and death. Specifically, there was no evidence of difference in overall complications, infection complications (including wound complications, sepsis, abscess, and anastomotic leakage), and noninfection complications (ileus, readmission, and return to operation), compared with no biological therapy and anti-TNF-α agents. At the same time, no significant evidence of difference was discovered in the comparison of preoperative UST and VDZ therapy in terms of overall complications, infectious complications (sepsis and abscess), and noninfectious complications (intestinal obstruction, readmission, and recovery surgery).
Conclusion
In general, compared with other biological agents, preoperative use of UST in the treatment of CD patients is usually safe and does not increase surgical complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, The Affiliated Hospital of Ningbo University, LiHuiLi Hospital, Ningbo, China.
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
- Nursing Department, Ningbo No. 2 Hospital, Ningbo, China.
Zitieren
APA
Li, L., Jiang, K., Lou, D., Zhang, M., Shi, Y., Shen, J., & Fu, X. (2023). Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients. European Surgical Research. https://doi.org/10.1159/000533594
Vancouver
Li L, Jiang K, Lou D, Zhang M, Shi Y, Shen J, et al. Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients. European Surgical Research. 2023. doi:10.1159/000533594
BibTeX
@article{Li2023,
author = {Li, Lingna and Jiang, Ke and Lou, Dandi and Zhang, Mengting and Shi, Yetan and Shen, Jingyi and Fu, Xiaojun},
title = {Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients},
journal = {European Surgical Research},
year = {2023},
doi = {10.1159/000533594}
}
EUVIMED